At Insife, we're not merely involved in pharmacovigilance; we're pioneers of innovation in drug safety. Our recently concluded annual convention was a testament to our commitment to driving change and shaping the future of this dynamic industry.
The first presentation was by our CEO, Martin, exploring emerging trends across regulatory agencies, pharmaceutical giants, biotech innovators, Contract Research Organizations (CROs), and service providers. What truly sets Insife apart is our strategic integration of cutting-edge technologies, such as Artificial Intelligence (AI) and ChatGPT, to drive advancements in pharmacovigilance. We're not just keeping up; we're leading the way.
The Keynote Address by Mick Foy, Director of Delivery at MHRA, unveiled the MHRA's SafetyConnect program, demonstrating how it seeks to unite all vigilance activities on shared technical platforms. This initiative aims to significantly enhance user experiences and, most importantly, bolster patient safety and knowledge. Insife's role in enhancing user experiences and improving patient safety through this program was a clear testament to our dedication.
James Whitehead, Senior Director, Device and Digital Safety, Global Patient Safety at AstraZeneca, ignited the audience's imagination with his vision of innovation and digital transformation in patient safety.
Dr. Marc Zittartz, Managing Director at Insife, presented HALOPV, our flagship PV solution, introducing the Latest Features and Modules.
Insife's Head of Strategic Partnering and US Consulting and Operations, Wilf Gilich, discussed the myriad benefits of partnering with Insife. With a focus on global service provision, Insife is poised to support its customers across the US and Europe.
Ea Marie Holst, Director of Pharmacovigilance Compliance at Novo Nordisk, shared insights into the innovations shaping her company's approach to PV together with HALOPV.
Anne Kraemmer, Safety Director at LINK Medical, emphasized the innovations within her renowned CRO and how they positively impact challenges faced by pharmaceutical companies. Insife's reach extends to the CRO landscape, showcasing our influence across the PV spectrum.
Jen Markey, Richard Salter, and Martin Holm-Petersen jointly presented PROHALO, a game-changing solution that promises to empower pharma companies, both large and small. Insife isn't just keeping up; we're setting the pace.
Andrew Bond, Director of Global Pharmacovigilance Agreements and Alliances at CSL Behring, highlighted how HALOPV can be leveraged to establish an efficient vendor oversight system for pharmacovigilance.
Jeffrey Ho, Interim Head of Pharmacovigilance and Patient Safety at Oncopeptides, echoed the sentiment by sharing why Oncopeptides chose HALOPV for signal management, how it uses it, and what its plans are for further leveraging the solution in the future.
Filip Beljan, Regulatory Intelligence Consultant & Product Owner at Insife, navigated the audience through global regulatory changes. His insights underlined Insife's commitment to ensuring compliance with evolving regulations.
During our event, we had two networking games: a prize for the person whose badge was scanned the most during the day, won by Anikta Singh from Ferring, and a prize for the person who submitted the best individual or group selfie, won by Priyanka Jain and the NNIT team!
Congratulations to the winners! And a big thank you to our speakers and presenters Anne Tinggaard, Louise Tan, and Mark Lee.
After the closing ceremony, we enjoyed drinks on the terrace, sharing experiences from the Convention.